Headlines about Cascadian Therapeutics (NASDAQ:CASC) have trended somewhat positive on Saturday, Accern Sentiment Analysis reports. The research group identifies positive and negative media coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Cascadian Therapeutics earned a media sentiment score of 0.05 on Accern’s scale. Accern also assigned news articles about the biopharmaceutical company an impact score of 45.4566504711222 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.
Shares of Cascadian Therapeutics (CASC) opened at $9.99 on Friday. The company has a market capitalization of $505.10, a PE ratio of -7.46 and a beta of 3.95. Cascadian Therapeutics has a fifty-two week low of $3.18 and a fifty-two week high of $10.21.
A number of equities research analysts have recently weighed in on the company. BidaskClub upgraded Cascadian Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, January 31st. ValuEngine upgraded Cascadian Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Wednesday, January 31st. Raymond James Financial downgraded Cascadian Therapeutics from an “outperform” rating to a “market perform” rating in a research report on Wednesday, January 31st. Finally, Zacks Investment Research downgraded Cascadian Therapeutics from a “hold” rating to a “sell” rating in a research report on Tuesday, January 9th. Three analysts have rated the stock with a sell rating, two have assigned a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus price target of $5.63.
About Cascadian Therapeutics
Cascadian Therapeutics, Inc, formerly Oncothyreon Inc, is a clinical-stage biopharmaceutical company. The Company focuses on the development of therapeutic products for the treatment of cancer. The Company’s clinical-stage product candidate includes ONT-380, an orally active and selective small-molecule human epidermal growth factor receptor (HER) 2 inhibitor.
Receive News & Ratings for Cascadian Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cascadian Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.